InVivoPure pH 8.0T Dilution Buffer
Product Description
Specifications
| Endotoxin |
<0.5 EU/mL (<0.0005EU/μL) Endotoxin level is determined using an LAL gel clotting test |
|---|---|
| Sterility | 0.2 μM filtered |
| Murine Pathogen Tests |
Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Minute Virus: Negative Mouse Hepatitis Virus: Negative Reovirus Screen: Negative Lymphocytic Choriomeningitis virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Mouse Rotavirus: Negative Theiler’s Murine Encephalomyelitis: Negative Ectromelia/Mousepox Virus: Negative Hantavirus: Negative Polyoma Virus: Negative Mouse Adenovirus: Negative Sendai Virus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Mouse Cytomegalovirus: Negative K Virus: Negative |
| Toxicity Test Results | Nontoxic and nonantigenic in animal models |
| Concentration | 1X |
| Volume | 50 ml |
| Composition |
35 mM Na2HPO4 1.7 mM NaH2PO4 136 mM NaCl 0.01% TWEEN® 80 This buffer does not contain calcium, magnesium, phenol red, or preservatives such as azide. Keep contents sterile. Open only in a biological safety cabinet. |
| Storage | 4°C |
Product Citations
-
-
Cardiovascular biology
-
Immunology and Microbiology
Programming Multifaceted Pulmonary T Cell Immunity by Combination Adjuvants.
In Cell Rep Med on 22 September 2020 by Marinaik, C. B., Kingstad-Bakke, B., et al.
PubMed
Induction of protective mucosal T cell memory remains a formidable challenge to vaccinologists. Using a combination adjuvant strategy that elicits potent CD8 and CD4 T cell responses, we define the tenets of vaccine-induced pulmonary T cell immunity. An acrylic-acid-based adjuvant (ADJ), in combination with Toll-like receptor (TLR) agonists glucopyranosyl lipid adjuvant (GLA) or CpG, promotes mucosal imprinting but engages distinct transcription programs to drive different degrees of terminal differentiation and disparate polarization of TH1/TC1/TH17/TC17 effector/memory T cells. Combination of ADJ with GLA, but not CpG, dampens T cell receptor (TCR) signaling, mitigates terminal differentiation of effectors, and enhances the development of CD4 and CD8 TRM cells that protect against H1N1 and H5N1 influenza viruses. Mechanistically, vaccine-elicited CD4 T cells play a vital role in optimal programming of CD8 TRM and viral control. Taken together, these findings provide further insights into vaccine-induced multifaceted mucosal T cell immunity with implications in the development of vaccines against respiratorypathogens, including influenza virus and SARS-CoV-2.
-